AfriPharma's long-term strategy: WHO-aligned sterile injectable manufacturing — anchored by distribution cash flows and DFI financing.
AfriPharma's manufacturing ambition is grounded in a deliberate sequencing: build distribution operations first, generate commercial cash flows, establish regulatory credibility, and then leverage that foundation to attract DFI financing for a world-class manufacturing facility.
This approach reduces execution risk, builds investor confidence, and ensures that manufacturing investment is backed by real market intelligence and established customer relationships across the SADC region.
AfriPharma's anchor manufacturing product — a paracetamol IV solution manufactured to EU GMP Annex 1 standards, targeting WHO Prequalification.
Sub-Saharan Africa imports the vast majority of its pharmaceutical supply. ParaFlow is designed to directly address that gap — manufacturing paracetamol IV locally within the SADC region and reducing dependence on distant supply chains.
Paracetamol IV is globally recognised as a critical medicine that every functioning health system must have reliably available. Producing it locally means Southern African health systems are no longer dependent on imports for one of their most essential drugs.
Most paracetamol IV used across Zimbabwe, Zambia, Botswana, and Mozambique is imported from India, Europe, or South Africa — creating supply chain fragility and price volatility that locally manufactured product directly eliminates.
A WHO-prequalified ParaFlow product can be purchased by UNICEF Supply Division, UNFPA, and government tender programs across Africa — giving AfriPharma access to large-scale institutional health contracts beyond the SADC region.
ParaFlow is designed from inception for WHO Prequalification — enabling institutional procurement access through UNICEF Supply Division, UNFPA, and national medicine tender programs across sub-Saharan Africa. A 36-month ICH Q1A/Q1B stability program has been developed to support the prequalification submission.
A four-phase roadmap — from healthcare access platform to regional pharmaceutical manufacturer.
Zimbabwe and Botswana entities operational. MCAZ WDP application in progress. Distribution platform and pharmacy services being established.
South Africa, Zambia, and additional SADC markets. Distribution cash flows established. DFI relationship development begins.
Manufacturing facility development. DFI financing secured (IFC, AfDB, DFC). WHO Prequalification submission for ParaFlow™.
Full-scale production. Institutional procurement access. SADC-wide distribution of AfriPharma-manufactured products.
